|
|
 |
|
Viewing report
|
|
|
|
U.S. Cell-Based Assays Markets
Frost & Sullivan, March 2008, Pages: 65
This Frost & Sullivan research titled U.S. Cell-based Assays Markets provides a comprehensive market forecast for the different type of assays employed to analyze cellular mechanisms. Cell growth-associated, cell death-associated assays, and functional cell assays used by life science researchers and drug developers are analyzed as individual segments in this study. The forecast was based on the types of applications employing these products, the saturation level among users of these products, as well new products that broaden the capabilities of existing ones and which may introduce new users to this market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: cell growth-associated assays, cell-death associated assays, and functional cell assays.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Cell growth-associated assays
- Cell death-associated assays
- Functional cell assays
Market Overview
Cell-based Assays Benefit Greatly from their Ability to Assess Expression and Functional Levels of Proteins and other Biomolecules
Various molecular signals that interact within cellular and extracellular environments to drive the cell in specified paths dictate the growth and maintenance of cells. As these signals also contribute to the development of many diseases, life science researchers as well as the pharmaceutical industry are looking to characterize and use them to understand the origin of diseases and find cures for them. 'Scientists appreciate the many different cellular signaling mechanisms and exploit them by developing assays that focus on a specific event that may shed light on the inner activity of a cell,' says the analyst of this research. 'Market participants continue to focus on the diversity of cellular interactions and the events that result from these interactions to develop cell-based assays for drug developers that aim to create drugs with more specificity and therefore more potency and for basic science researchers who study basic biological mechanisms and diseases at the molecular level.'
Advancements in tools used for genomic and proteomic analyses have enabled scientists to study cells at higher specificities, while also increasing the number of discoveries and understanding of molecular players. These individual cellular component assessments have been accelerated by the development of cell-based assays that provide careful evaluations based on isolated analysis. These assays have and will succeed commercially, since drug developers continue to demand them for expanding and replenishing their drug portfolios. Although competitive technologies that provide similar analyses may impinge on the market growth, the value provided by cell-based assays is not yet replaceable by a single methodology. Meanwhile, high-throughput processing of samples is likely to drive down per sample costs, compelling the market to achieve economies of scale.
Tailored Assays are the Way Forward in the U.S. Cell-based Assays Market
The market is likely to swell with increasing investments in drug discovery efforts to support the pharmaceuticals industry. Moreover, the market is expected to expand to accommodate greater numbers of participants, as specialized products are needed to provide a greater understanding of the workings of cells. Market participants continue to identify new areas of market growth and have adjusted their products to match them.
For instance, the diverse demographics and age groups could result in different diseases, which will, in turn, drive the demand for tailored therapies. To deal with this expected growth in disease profiles, the drug discovery industry is looking to develop medicines based on specific biomarker profiles. 'These profiles represent an analysis of many different signals that may indicate a disease and are reliable in predicting the presence of a disease and patient outcome,' notes the analyst. 'Drugs can be developed to meet these biomarker profiles and tested to satisfy specific endpoints using cell-based assays.'
Customers who bought this item also bought
European Cell Based Assays Markets
Cell-Based Assays for Drug Discovery
Development of Cell-Based Assays (Technical Insights)
Cell-Based Assays: Commercial Opportunities, Legal Trends, and Technology Analyses
Validation of Cell-Based Assays in the GLP Setting: A Practical Guide
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
US Stem Cell Market Analysis
Cell Therapy - Technologies, Markets and Companies
Stem Cell Research 2008
Cell Therapy Markets
Stem Cell Markets
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
|
|
|
|
